 |
Overview
|
|
QLT Inc. is a biotechnology company dedicated to the development and commercialization of innovative therapies for the eye. We are focused on our commercial product Visudyne® for the treatment of wet-AMD, developing drugs to be delivered in our proprietary punctal plug delivery system, as well as developing our synthetic retinoid program for the treatment of certain inherited retinal diseases.
Our vision is to be a leading ocular company bringing innovative therapies to patients and the medical community. The company's strategy is straightforward:
- Maximize the revenue of our commercial product: Visudyne.
- Continue to build a strong ocular pipeline through early-stage development, clinical trials, in-licensing and other expansion opportunities.
- Manage the business for growth.
|
|
|
| |
|
|
|
|
|
|
|
|
